IL295142A - Formulations for the vaccine against the corona virus - Google Patents

Formulations for the vaccine against the corona virus

Info

Publication number
IL295142A
IL295142A IL295142A IL29514222A IL295142A IL 295142 A IL295142 A IL 295142A IL 295142 A IL295142 A IL 295142A IL 29514222 A IL29514222 A IL 29514222A IL 295142 A IL295142 A IL 295142A
Authority
IL
Israel
Prior art keywords
cov
seq
amino acids
mutation
glycoprotein
Prior art date
Application number
IL295142A
Other languages
English (en)
Hebrew (he)
Inventor
Gale Smith
Michael J Massare
Jing-Hui Tian
Original Assignee
Novavax Inc
Gale Smith
Michael J Massare
Tian jing hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed by Novavax Inc, Gale Smith, Michael J Massare, Tian jing hui filed Critical Novavax Inc
Publication of IL295142A publication Critical patent/IL295142A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL295142A 2020-01-27 2021-01-27 Formulations for the vaccine against the corona virus IL295142A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Publications (1)

Publication Number Publication Date
IL295142A true IL295142A (en) 2022-09-01

Family

ID=77079351

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295142A IL295142A (en) 2020-01-27 2021-01-27 Formulations for the vaccine against the corona virus

Country Status (14)

Country Link
US (1) US20230070886A1 (OSRAM)
EP (1) EP4097123A4 (OSRAM)
JP (2) JP7792339B2 (OSRAM)
KR (1) KR20220141302A (OSRAM)
CN (1) CN115720581A (OSRAM)
AU (1) AU2021214064A1 (OSRAM)
BR (1) BR112022014830A2 (OSRAM)
CA (1) CA3165371A1 (OSRAM)
GB (1) GB2610070A (OSRAM)
IL (1) IL295142A (OSRAM)
MX (1) MX2022009167A (OSRAM)
TW (1) TW202142555A (OSRAM)
WO (1) WO2021154812A1 (OSRAM)
ZA (1) ZA202401922B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN113521269A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
BR112023023035A2 (pt) * 2021-05-05 2024-01-23 Novavax Inc Composições de coronavírus e influenza e métodos para usá-las
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
CN115960252A (zh) * 2021-08-26 2023-04-14 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
CN118900845A (zh) * 2021-11-24 2024-11-05 旗舰创业创新六公司 冠状病毒免疫原组合物及其用途
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US20250025549A1 (en) * 2021-11-30 2025-01-23 Novavax, Inc. Coronavirus vaccine formulations
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
TW202500574A (zh) * 2023-05-12 2025-01-01 美商伊科薩瓦克斯有限公司 冠狀病毒刺突醣蛋白受體結合域及其用途
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
EP2478760A1 (en) * 2005-05-10 2012-07-25 Monsanto Technology LLC Genes and uses for plant improvement
KR101691574B1 (ko) * 2008-12-09 2017-01-02 노바백스, 인코포레이티드 변형 ｒｓｖ ｆ 단백질 및 이들의 사용 방법
SG10201602434UA (en) * 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
HK1225631A1 (zh) * 2013-09-19 2017-09-15 Novavax, Inc. 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
IL257800B2 (en) * 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
WO2017161151A1 (en) * 2016-03-16 2017-09-21 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
EP4599847A3 (en) * 2016-10-25 2025-11-12 Trustees of Dartmouth College Prefusion coronavirus spike proteins and their use
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Also Published As

Publication number Publication date
ZA202401922B (en) 2025-04-30
WO2021154812A1 (en) 2021-08-05
CA3165371A1 (en) 2021-08-05
EP4097123A1 (en) 2022-12-07
AU2021214064A1 (en) 2022-08-18
GB2610070A (en) 2023-02-22
US20230070886A1 (en) 2023-03-09
JP2023512648A (ja) 2023-03-28
KR20220141302A (ko) 2022-10-19
GB202212336D0 (en) 2022-10-12
JP2026026092A (ja) 2026-02-16
TW202142555A (zh) 2021-11-16
EP4097123A4 (en) 2024-02-14
MX2022009167A (es) 2022-08-17
BR112022014830A2 (pt) 2022-09-27
JP7792339B2 (ja) 2025-12-25
WO2021154812A8 (en) 2022-02-24
CN115720581A (zh) 2023-02-28

Similar Documents

Publication Publication Date Title
US11253586B2 (en) Coronavirus vaccine formulations
JP7792339B2 (ja) コロナウイルスワクチン製剤
US20220332765A1 (en) Coronavirus vaccine formulations
IL257800B1 (en) Immune compositions with improved stability and immunogenicity
US20250025549A1 (en) Coronavirus vaccine formulations
US20240423926A1 (en) Methods and compositions for treating respiratory disease
RU2845642C1 (ru) Вакцинные составы против коронавируса
EP4704893A2 (en) Sars-cov-2 vaccine compositions
HK40088999A (zh) 冠状病毒疫苗配制品